McNicoll, Lewis & Vlak Reiterates Alnylam Pharmaceuticals Buy, $15 PT

McNicoll, Lewis & Vlak reiterated its Alnylam Pharmaceuticals ALNY Buy rating and $15 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "In our opinion, RNAi represents the next major therapeutic class; it has the potential to transform the biotechnology and pharmaceutical industries, similar to the transformation made by both recombinant DNA and monoclonal antibodies." Shares of Alnylam Pharmaceuticals were trading at $9.37 at the time of posting, down 0.74% from Friday's market close.